Ultragenyx Stays On JPMorgan’s Focus List As Analyst Highlights Strong Long-Term Positioning

JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117.

Latest Ratings for RARE

DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022JP MorganUpgradesNeutralOverweight Feb 2022Morgan StanleyMaintainsOverweight

View More Analyst Ratings for RARE

View the Latest Analyst Ratings

read more